The study provides a clue to reactivate p53 tumor suppressor function by synergistically applying Mdm2 and MdmX inhibitors in cancer cells, and affords new therapeutic opportunities for simultaneously inhibiting both Mdm2 and MdmX to restore p53 using drug combinations or dual-inhibitory drugs [70-72]. Here, TP53 is linked to neoplasm.